Aethlon Medical Cash on Hand 2010-2024 | AEMD

Aethlon Medical cash on hand from 2010 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Aethlon Medical Annual Cash on Hand
(Millions of US $)
2024 $5
2023 $15
2022 $17
2021 $10
2020 $10
2019 $4
2018 $7
2017 $2
2016 $2
2015 $1
2014 $1
2013 $0
2012 $0
2011 $0
2010 $0
2009 $0
Aethlon Medical Quarterly Cash on Hand
(Millions of US $)
2024-09-30 $7
2024-06-30 $9
2024-03-31 $5
2023-12-31 $8
2023-09-30 $10
2023-06-30 $13
2023-03-31 $15
2022-12-31 $18
2022-09-30 $20
2022-06-30 $15
2022-03-31 $17
2021-12-31 $20
2021-09-30 $23
2021-06-30 $25
2021-03-31 $10
2020-12-31 $12
2020-09-30 $14
2020-06-30 $16
2020-03-31 $10
2019-12-31 $4
2019-09-30 $1
2019-06-30 $2
2019-03-31 $4
2018-12-31 $5
2018-09-30 $5
2018-06-30 $6
2018-03-31 $7
2017-12-31 $6
2017-09-30 $1
2017-06-30 $0
2017-03-31 $2
2016-12-31 $1
2016-09-30 $1
2016-06-30 $1
2016-03-31 $2
2015-12-31 $3
2015-09-30 $4
2015-06-30 $6
2015-03-31 $1
2014-12-31 $3
2014-09-30 $1
2014-06-30 $1
2014-03-31 $1
2013-12-31 $2
2013-09-30 $0
2013-06-30 $0
2013-03-31 $0
2012-12-31 $0
2012-09-30 $0
2012-06-30 $1
2012-03-31 $0
2011-12-31 $0
2011-09-30 $0
2011-06-30 $0
2011-03-31 $0
2010-12-31 $0
2010-09-30 $0
2010-06-30 $0
2010-03-31 $0
2009-12-31 $0
2009-09-30 $0
2009-06-30 $0
2009-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Health Maintenance Organizations $0.006B $0.001B
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.
Stock Name Country Market Cap PE Ratio
UnitedHealth Group (UNH) United States $450.249B 18.11
Cigna Group (CI) United States $76.436B 10.00
Centene (CNC) United States $30.145B 8.85
Humana (HUM) United States $28.391B 12.93
Molina Healthcare (MOH) United States $16.789B 13.35
Select Medical Holdings (SEM) United States $2.364B 8.19
Joint (JYNT) United States $0.154B 93.54